Alzheimer's Therapeutic Research Institute
25
5
7
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 25 trials
100.0%
+13.5% vs industry average
8%
2 trials in Phase 3/4
27%
3 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
Role: collaborator
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
Role: collaborator
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Role: collaborator
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
Role: collaborator
The Progressive Supranuclear Palsy Clinical Trial Platform
Role: collaborator
Alzheimer's Disease Neuroimaging Initiative 4
Role: collaborator
Alzheimer's Disease Neuroimaging Initiative 3
Role: collaborator
Alzheimer's Tau Platform: Master Protocol
Role: collaborator
Alzheimer's Tau Platform: Regimen A - AADvac1
Role: collaborator
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Role: collaborator
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
Role: collaborator
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
Role: collaborator
In-Person Recruitment of Individuals to the Alzheimer's Prevention Trial (APT) Webstudy
Role: collaborator
Memory Improvement Through Nicotine Dosing (MIND) Study
Role: collaborator
Financial Incentives and Recruitment to the APT Webstudy
Role: collaborator
Alzheimer's Plasma Extension
Role: collaborator
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Role: collaborator
Alzheimer's Disease Neuroimaging Initiative 2
Role: collaborator
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
Role: collaborator
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Role: collaborator